Without going into the discussion of private vs socialized (it works for many other countries, so don't blame national healthcar for the ineptness of your government), it is fairly easy to see that an X amount of care is needed, costing Y amount of money.
The Y amount is what we would collectively pay through social taxing. Outisde of the providers and the materials, noone is benefiting from the giving of care.
In the US, extra money needs to be paid for massive profits of the insurance companies (A), as well as insurance of all providers against malpractice (B), as well as lawyer fees for all disputes (C), as well as penalties which are just charged back to the users (D) as well as all the personall involved solely in running the papermill of this entire structure (E).
So you end up paying not just Y, but Y + A + B + C + D + E.
The problem, as I see it, is that "Y" does not take into account some very important issues.
Countries such as Canada and France mandate costs of medical innovations such as drugs. For instance, if you want to have your drug used in such countries, you can only sell it in that country for $X. That means that someone else, somewhere, must pay for the costs of development, research, and testing for that drug. Due to the fact that the cost of those drugs can't be shared equitably amongst selling countries, the country where there are no price controls pays the lions share.
This is especially exacerbated since most medical innovation come from at least in part, the United States. According to the 2004 "Economic Report to the President", eight of the last ten most important medical innovations were developed at least in part in the United States (with one being of indeterminate origin and the other being Switzerland).
The top
five hospitals in the U.S. conduct more clinical trials then in
all of the hospitals in any single other country. In only five of the last 34 did a scientist in the United States not win or share in the Nobel Prize for Medicine or Physiology.
The point of all this is to say that these developments cost money, and not just in profits for medical companies. Money which other countries refuse to pay an equal share in, and therefore the costs of these burdens are laid at the feet of the American health care consumer.
These cost also are considering that the B, C, D and E issues which you brought up are also not paid for by those of non-American countries.